Fosaprepitant dimeglumine - CAS 172673-20-0
Catalog number: 172673-20-0
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
Neurokinin Receptor
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Appearance:
white solid powder
Synonyms:
Fosaprepitant; Fosaprepitant dimeglumine, Emend; Inemend. UNII-D35FM8T64X; MK-0517; MK 0517; MK0517.
MSDS:
Inquire
1.Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
Tsuda T1, Kyomori C2, Mizukami T1, Taniyama T1, Izawa N1, Horie Y1, Hirakawa M1, Ogura T1, Nakajima TE1, Tsugawa K3, Boku N1. Mol Clin Oncol. 2016 Apr;4(4):603-606. Epub 2016 Feb 5.
The incidences of infusion site adverse events in chemotherapy regimens, including anthracyclines with either fosaprepitant or aprepitant as the anti-emetic, were not highlighted in the randomized trial comparing aprepitant and fosaprepitant. The present retrospective analysis was performed in breast cancer patients receiving anthracycline-containing chemotherapy, a combination of epirubicin and cyclophosphamide with or without 5-fluorouracil as the adjuvant or neoadjuvant, at the outpatient infusion center of St. Marianna University Hospital (Kawasaki, Japan). Infusion site adverse events were retrospectively compared between the 3 months prior to and three months following switching from 3 day oral administration of aprepitant to intravenous infusion of fosaprepitant. A total of 62 patients were included in the aprepitant group and 38 in the fosaprepitant group. Of these patients, 26 (42%) in the aprepitant group and 36 patients (96%) in the fosaprepitant group experienced any grade of infusion site adverse events at least once (P<0.
2.Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
Adra N1, Albany C2, Brames MJ2, Case-Eads S2, Johnson CS3, Liu Z3, Fausel CA2, Breen T4, Hanna NH2, Hauke RJ5, Picus J6, Einhorn LH2. Support Care Cancer. 2016 Feb 2. [Epub ahead of print]
PURPOSE: A phase III study adding aprepitant to a 5HT3 receptor antagonist (5HT3-RA) plus dexamethasone in germ cell tumor (GCT) patients treated with 5-day cisplatin combination chemotherapy demonstrated a significant improvement in complete response (CR) (J Clin Onc 30:3998-4003, 2012). Fosaprepitant has demonstrated non-inferiority compared to aprepitant in single-day cisplatin chemotherapy and is approved as a single-dose alternative. This single-arm phase II study is the first clinical trial evaluating fosaprepitant in patients receiving multi-day cisplatin regimen.
3.Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice.
Dushenkov A1, Kalabalik J2, Carbone A2, Jungsuwadee P2. J Oncol Pharm Pract. 2016 Feb 25. pii: 1078155216631408. [Epub ahead of print]
PURPOSE: Aprepitant and its parenteral formulation fosaprepitant are widely used for the prevention of chemotherapy-induced nausea and vomiting. Aprepitant exerts modest inhibitory effect on CYP3A4 and modest inductive effect on CYP2C9 substrates such as some antineoplastics and multiple other medications. This article is aimed to provide pharmacists and other healthcare professionals with an updated summary of drug-drug interactions of aprepitant/fosaprepitant and implications for clinical practice.
4.Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice.
Dushenkov A1, Kalabalik J2, Carbone A2, Jungsuwadee P2. J Oncol Pharm Pract. 2016 Feb 25. pii: 1078155216631408. [Epub ahead of print]
PURPOSE: Aprepitant and its parenteral formulation fosaprepitant are widely used for the prevention of chemotherapy-induced nausea and vomiting. Aprepitant exerts modest inhibitory effect on CYP3A4 and modest inductive effect on CYP2C9 substrates such as some antineoplastics and multiple other medications. This article is aimed to provide pharmacists and other healthcare professionals with an updated summary of drug-drug interactions of aprepitant/fosaprepitant and implications for clinical practice.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Neurokinin Receptor Products


Talnetant hydrochloride
(CAS: 204519-66-4)

Talnetant is the hydrochloride salt of Talnetant. Talnetant, also called as SB 223412, is a selective, competitive, nonpeptide NK3 receptor antagonist and is in...

CAS 147116-67-4 Maropitant

Maropitant
(CAS: 147116-67-4)

CAS 170729-80-3 Aprepitant

Aprepitant
(CAS: 170729-80-3)

CAS 214487-46-4 MEN11467

MEN11467
(CAS: 214487-46-4)

MEN11467, a pseudopeptide,is a new tachykinin NK1 receptor antagonist which potently antagonizes both tachykinin and antigen-mediated inflammatory responses of ...

CAS 172673-20-0 Fosaprepitant dimeglumine

Fosaprepitant dimeglumine
(CAS: 172673-20-0)

CAS 2507-24-6 Physalaemin

Physalaemin
(CAS: 2507-24-6)

Physalaemin, a non-mammalian tachykinin originally isolated from the Physalaemus frog, binds selectively to neurokinin-1 (NK1) receptor with high affinity.

CAS 914462-92-3 Rolapitant HCl hydrate

Rolapitant HCl hydrate
(CAS: 914462-92-3)

Rolapitant, also known as SCH-619734, is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist with potential antiemetic activity. Unl...

CAS 148687-76-7 L-733,060 hydrochloride

L-733,060 hydrochloride
(CAS: 148687-76-7)

The hydrochloride salt form of L-733,061, a phenylpiperidine derivative, has been found to be a NK1 receptor antagonist that could probably be antidepressant/ a...

CAS 148700-85-0 L-733,060

L-733,060
(CAS: 148700-85-0)

L-733,061, a phenylpiperidine derivative, has been found to be a NK1 receptor antagonist that could probably be antidepressant/ anxiolytic agent and also show a...

CAS 290297-26-6 Netupitant

Netupitant
(CAS: 290297-26-6)

Netupitant is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the activity o...

CAS 160492-56-8 Osanetant

Osanetant
(CAS: 160492-56-8)

Osanetant is a non-peptide neurokinin 3 (NK3) receptor antagonist. It is developed for the treatment of schizophrenia and other central nervous system (CNS) dis...

CAS 33507-63-0 Substance P

Substance P
(CAS: 33507-63-0)

Substance P, a neuropeptide, is a sensory neuropeptide and inflammatory mediator. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor...

CAS 86933-75-7 Neurokinin B

Neurokinin B
(CAS: 86933-75-7)

Neurokinin B, one of the tachykinin family of peptides, binds a family of GPCRs—including neurokinin receptor 1 (NK1R), NK2R, and NK3R to mediate their biologic...

CAS 122063-01-8 [bAla8]-Neurokinin A(4-10)

[bAla8]-Neurokinin A(4-10)
(CAS: 122063-01-8)

An agonist of neurokinin 2 (NK2) receptor

CAS 63968-82-1 Kassinin

Kassinin
(CAS: 63968-82-1)

Kassinin, a tachykinin peptide derived from the Kassina frog, is secreted as a defense response, and is involved in neuropeptide signalling and shows selectivit...

CAS 110880-55-2 [Sar9,Met(O2)11]-Substance P

[Sar9,Met(O2)11]-Substance P
(CAS: 110880-55-2)

A selective agonist of tachykinin NK1 receptor

CAS 86933-74-6 Neurokinin A

Neurokinin A
(CAS: 86933-74-6)

Neurokinin A is a member of the endogenous tachykinin agonist with preference for the NK-2R (NK-2 receptor).

CAS 97559-35-8 Neurokinin A(4-10)

Neurokinin A(4-10)
(CAS: 97559-35-8)

Neurokinin A (4-10), an endogenous neuromodulatory peptide formerly known as substance K, is atachykinin NK2 receptor agonist.

CAS 137593-52-3 GR 64349

GR 64349
(CAS: 137593-52-3)

GR 64349 is a potent and selective agonist of tachykinin NK2 receptor (EC50 = 3.7 nM in rat colon).

Chemical Structure

CAS 172673-20-0 Fosaprepitant dimeglumine

Quick Inquiry

Verification code

Featured Items